Winona’s capsule page names progesterone USP and lists inactive ingredients. A separate page describes a cream containing three hormones. Reading only the common word progesterone would conceal those differences, as well as the separate question of what the company’s approval and compounding statements actually cover.
This review is dated September 29, 2026 and examines those product pages with the service FAQ. Its focus is the distance between an ingredient name and a fully identified medicine. It contains no purchase, laboratory analysis or assessment of how either preparation performed for a patient.
Read this article by section
USP appears in an ingredient description, not a supplied-product certificate
The capsule record lists progesterone USP as the active ingredient. It also publishes inactive ingredients including peanut oil and gelatin. The wording does not itself identify a manufacturer, authenticate a batch or supply an independent approval record for what a patient eventually receives.
The important reading step is to preserve what is stated without adding properties that were not documented. Our micronized meaning guide addresses another word that can be mistaken for a complete product description. Neither term replaces the rest of a label. Evernow’s assessment considers the more limited situation where a treatment page does not provide the same ingredient detail.
The combination cream is a different medicine record
Winona’s body-cream page identifies estradiol, estriol and progesterone. It should not be shortened to progesterone cream in a way that erases the other active hormones. The page describes compounding, while the capsule listing presents a different preparation.
A comparison of the two would need the intended purpose and complete prescription, not just whether both contain progesterone. The oral, vaginal and topical guide keeps route and formulation distinctions visible. A body cream containing multiple hormones is not automatically a substitute for a single-hormone oral product, and neither product description instructs a reader to move between routes or assemble a combined plan independently.
Conflicting FAQ language cannot settle approval for the order
One part of Winona’s FAQ describes its hormone treatments broadly as compounded. Another distinguishes approved tablets, capsules and patches from compounded creams. The review retains that inconsistency rather than deciding that either sentence establishes the status of every product.
FDA’s compounding explanation provides the relevant boundary: compounded drugs are not FDA-approved finished products. The bioidentical-and-approval discussion therefore asks which exact preparation a claim concerns. Before the regulatory description can be useful, the provider or pharmacist needs to identify the actual medicine. A broad company statement cannot replace that product-level answer or independently verify the preparation proposed to one patient. The ingredient name can remain the same while the number of active components, preparation and regulatory record differ. Those differences belong in the explanation even when the same company offers both products.
An ingredient alternative still needs evidence for its intended role
The capsule page presents cream as an alternative in the context of peanut allergy and makes an equivalence claim about uterine protection. These are separate propositions: avoiding a declared ingredient does not establish that a different preparation fulfills the same clinical purpose.
The BMS protection tool, internally reviewed in February 2026, discusses variable absorption and inadequate evidence for endometrial protection with compounded transdermal progesterone. That is UK professional guidance, not testing of Winona’s product. It explains why this review does not adopt the company’s protection comparison or give personal allergy clearance. The actual formulation and intended use both require professional assessment rather than a website substitution.
Customer access does not follow from ingredient identity
Winona’s FAQ limits hormone plans to ages 35–59 and enumerates the locations served. Recognizing an active ingredient does not remove those program conditions or establish medical suitability within the stated range.
The care model is asynchronous: the FAQ does not offer physician phone or video appointments and describes typical message replies within twenty-four to forty-eight hours, sometimes longer. That distinction makes Gennev’s visit-based review a useful service comparison. It is not evidence that one delivery model is clinically superior. The relevant question is how a product or treatment concern reaches the professional responsible, without mistaking continuous message submission for an immediate clinical response.
Starting prices describe different recurring products
The capsule starts at $39 per month; the three-hormone cream starts at $89. These figures do not identify a selected quantity or recommend buying both. The FAQ says a thirty-day supply is processed every twenty-eight days and a ninety-day supply every eighty-four days unless the subscription is paused or canceled.
Standard shipping is described as free, with charges for faster options, and Winona does not bill insurance directly. An order has a twenty-four-hour cancellation-and-refund window before processing prevents reversal. Canceling future recurring orders is a different action. Those timing conditions belong beside the advertised monthly prices when identifying what would actually be purchased.
Keep the capsule record separate from the treatment decision
Winona’s published capsule ingredients are more informative than an unspecified hormone menu, but they cannot establish a personal prescription or guarantee protection and symptom relief. The page’s detail also does not authorize assigning its inactive ingredients to another manufacturer’s capsule.
The useful next step in a professional discussion is an exact product identification and an explanation of why that form has been proposed. Its own label, ingredients and approval status can then be considered with the intended treatment. This review confirms the capsule and combination-cream offers while preserving the difference between provider statements, professional evidence and properties that have not been independently verified.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Winona: Progesterone CapsulesProvider oral-product listing; peanut oil and gelatin declared, starting price and broad cream-equivalence claims separated, no actual manufacturer or shipment authenticated · Checked 2026-09-29
- Winona: Estrogen Body Cream with ProgesteroneProvider compounded estradiol/estriol/progesterone cream and starting price; uterine-protection and safety language attributed, not independently demonstrated · Checked 2026-09-29
- Winona: Frequently Asked QuestionsProvider clinical and subscription conditions; age 35–59, listed jurisdictions, asynchronous care, differing approval descriptions, 28/84-day processing and 24-hour order window · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
- British Menopause Society: Progestogens and Endometrial Protection (reviewed February 2026)UK professional guidance internally reviewed February 2026, May 2026 file version; compounded transdermal progesterone evidence and absorption limitations, no claim of testing a reviewed brand · Checked 2026-09-29